Mathieu Chantal
UZ Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.
Expert Opin Drug Metab Toxicol. 2006 Oct;2(5):779-91. doi: 10.1517/17425255.2.5.779.
Inhaled human insulin ((insulin human [rDNA origin]) Inhalation Powder) is a prandial insulin approved in the EU and the US for the treatment of adults with diabetes. Its glycaemic control is comparable to subcutaneous insulin in Type 1 and 2 diabetes, and has superior efficacy versus oral antidiabetic agents in Type 2 diabetes. Hypoglycaemia and mild-to-moderate cough are the main side effects. The treatment group differences in pulmonary function occur early, and are small, nonprogressive for up to 2 years and reversible following discontinuation. Patient-reported outcomes data displays higher diabetes treatment satisfaction, improvements in some quality-of-life scores, and treatment preference with inhaled human insulin versus traditional means. Availability of inhaled insulin may increase insulin acceptance and thus improve glycaemic control in patients with diabetes.
吸入用重组人胰岛素（（重组人胰岛素[rDNA 来源]）吸入粉）是一种在欧盟和美国获批用于治疗成人糖尿病的餐时胰岛素。在 1 型和 2 型糖尿病中，其血糖控制效果与皮下注射胰岛素相当，且在 2 型糖尿病中，其疗效优于口服抗糖尿病药物。低血糖和轻至中度咳嗽是主要副作用。肺功能方面的治疗组差异出现较早，差异较小，长达 2 年无进展，停药后可逆转。患者报告的结果数据显示，糖尿病治疗满意度更高，一些生活质量评分有所改善，与传统治疗方式相比，患者更倾向于吸入用重组人胰岛素治疗。吸入胰岛素的可获得性可能会提高患者对胰岛素的接受度，从而改善糖尿病患者的血糖控制。
